Lottare GBM SIGNED
LOcalized Targeted Therapy to Avoid REcurrent GlioBlastoma Multiforme
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Lottare GBM project word cloud
Explore the words cloud of the Lottare GBM project. It provides you a very rough idea of what is the project "Lottare GBM" about.
Project "Lottare GBM" data sheet
The following table provides information about the project.
| Coordinator |
TARGTEX SA
Organization address contact info |
| Coordinator Country | Portugal [PT] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-12-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | TARGTEX SA | PT (Torres Vedras) | coordinator | 50˙000.00 |
Map
Project objective
TargTex is a newly founded Portuguese startup with a novel concept to tackle the most lethal type of brain tumor – Glioblastoma Multiforme (GBM). GBM is the most common and aggressive type of primary brain tumor, with a survival rate lower than 5% after 2 years. The aggressiveness of the disease combined with the lack of effective treatments translates into a terrible prognosis to GBM patients, with a life expectancy of no more than 12 to 18 months after being diagnosed. TargTex team has developed a concerted approach, taking into consideration the needs and contributions from key stakeholders: patients, doctors and scientists. This innovative treatment (for which we have IP protecting the application) is based on a hydrogel formulation to be used as adjunct to surgery, applied after tumor resection. With a slow release from the hydrogel – over several weeks – the molecule is able to selectively kill GBM tumor cells that were not fully removed during surgery, thus offering a safer solution to neurosurgeons, who often deal with the conundrum of removing unaffected brain tissue to avoid tumor recurrence. In addition, this approach brings added benefits to the patients since the single treatment does not require further chemotherapy cycles. Most importantly, the active drug is a small molecule that binds to a specific target in GBM cells, and therefore, covers the whole patient population since it is not a personalized medicine. Our goal for the Phase 1 is to assess the technical, commercial and financial feasibility of TargTex. For that purpose, we will a) assess the regulatory framework and IP strategy to develop an adjunct to surgery in the context of GBM; 2) design the Toxicology & Safety Pharmacology experiments needed for an EMA’s Clinical Trial application; 3) assess the willingness to adoption of our solution from neuro-oncologists and neurosurgeons and 4) evaluate competition and assess the interest of investors and pharma towards our unique product.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOTTARE GBM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LOTTARE GBM" are provided by the European Opendata Portal: CORDIS opendata.